Debiopharm and Ascepion Announce an Exclusive License Agreement

News   Jun 19, 2012

 
Debiopharm and Ascepion Announce an Exclusive License Agreement
 
 
 

RELATED ARTICLES

Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until Now

News

A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.

READ MORE

Researchers Reveal How Superbug Secretes It’s Toxin

News

Monash University’s Biomedicine Discovery Institute (BDI) researchers have created the first high-resolution structure depicting a crucial part of the ‘superbug’ Pseudomonas aeruginosa. The image identifies the ‘nanomachine’ used by the highly virulent bacteria to secrete toxins, pointing the way for drug design targeting this.

READ MORE

Scientists Develop a Synthetic Solution to Combat Dwindling Supply of Cancer and HIV Drug

News

Supplies of a promising drug for cancer, HIV and possibly other diseases is dwindling, and scientists have struggled to extract more from the marine creatures who produce it. Now, chemists have a synthetic solution.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE